ORIGINAL ARTICLE CHANGES IN HEMOSTASIS AND LIPID METABOLISM IN POSTMENOPAUSAL WOMEN RECEIVING HORMONE REPLACEMENT THERAPY: EFFECTS OF NATURAL AND SYNTHETIC PROGESTOGENS Li-Fen Teng, Fang-Ping Chen*, Ning Lee 1 Department of Obstetrics and Gynecology, and 1 Department of Clinical Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. SUMMARY Objective: In this study, we evaluated hemostatic factors related to cardiovascular disease in postmenopausal women receiving estrogen or combined progestogen replacement therapy. We further compared the effects of natural and synthetic progestogens on lipid profiles and hemostatic factors. Materials and Methods: Of the 60 subjects, 20 who had undergone a hysterectomy used conjugated equine estrogen (CEE; 0.625 mg/day) alone (group I); the other 40 used CEE (0.625 mg/day for 21 days) plus either micronized progesterone (200 mg/day; group II; n = 20) or medroxyprogesterone acetate (10 mg/day; group III; n = 20) for the final 10 days. The effects on lipid profiles and hemostatic parameters were evaluated at baseline and after 6 and 12 months of treatment. Results: Only group I patients showed a significant reduction in low-density lipoprotein cholesterol (LDL-C) and the atherogenic ratios of total cholesterol/high-density lipoprotein cholesterol (HDL-C) and LDL-C/HDL-C, as well as an increase in triglycerides. Tissue plasminogen activator levels decreased significantly in group I but did not change in groups II or III. Antithrombin III and protein S levels decreased significantly in group I but increased in groups II and III. Group I patients showed a stronger increase in protein C than those in either group II or III. There were no significant differences in hemostatic parameters between groups II and III. Conclusions: Estrogen replacement therapy may have beneficial effects on lipid profile and fibrinolytic factors in postmenopausal women. Both natural and synthetic progestogens attenuated the effects of estrogen. The 1-year effects of hormone replacement therapy on factors related to venous thromboembolism were positive. Micronized progesterone was not superior to medroxyprogesterone acetate. [Taiwanese J Obstet Gynecol 2004; 43(2):80 87] Key Words: hemostatic factors, estrogen replacement therapy, progestogens, lipid profile, hormone replacement therapy Introduction *Correspondence to: Dr. Fang-Ping Chen, Department of Obstetrics and Gynecology, Keelung Chang Gung Memorial Hospital, 222 Mai-Chin Road, Keelung 200, Taiwan. E-mail: fangping@cgmh.org.tw Received: July 15, 2003 Revised: September 23, 2003 Accepted: November 5, 2003 Cardiovascular disease is the leading cause of death in developed countries. Premenopausal women have lower cardiovascular morbidity and mortality than men of a similar age. However, after menopause, the incidence of cardiovascular disease increases and the prevalences of cardiovascular disease in men and women are similar during the eighth decade of life [1,2]. More than 30 80
HRT & Cardiovascular Risk Factors epidemiologic studies have found that postmenopausal women who use estrogen are at a lower risk of coronary disease than those who do not [3]. This further supports the theory that the female sex hormones have beneficial effects on cardiovascular disease. Progestogen added to estrogen reduces or eliminates the excess risk of endometrial cancer due to the unopposed effect of estrogen. The use of progestogens combined with estrogen is now common, but information about the risk of cardiovascular disease associated with combined therapy is limited. Grodstein et al reviewed 59,337 women who participated in the Nurses Health Study and suggested that the addition of progestin did not appear to attenuate the cardiovascular effects of postmenopausal estrogen therapy [4]. However, experimental data suggest that the addition of progestin may diminish the apparent cardioprotective effects of hormone therapy on lipoprotein metabolism [5,6], arterial dilatation, and blood flow [7]. Furthermore, in the Heart and Estrogen/Progestin Replacement Study (HERS) [8], postmenopausal women with established coronary heart disease who received estrogen plus progestin did not experience a reduction in overall risk of adverse cardiovascular outcomes. This indicates that the effects of various progestogens on cardiovascular risk factors require further evaluation. The aim of this study was not only to evaluate the effect of hormone replacement therapy (HRT) on cardiovascular risk factors, including lipoprotein metabolism and hemostatic factors, but also to compare the effects between natural progesterone and progestin. Materials and Methods Subjects From January 1997 to December 1998, a total of 60 healthy postmenopausal women with climacteric syndrome and without evidence of gynecologic disorders voluntarily joined this study. All women had been amenorrheic for 1 year or longer or had a plasma estradiol level of less than 40 pg/ml and a plasma follicular stimulating hormone level of more than 30 miu/ml. They had not received HRT for at least 3 months prior to enrollment and had no contraindications for estrogen or progestogen treatment. None had a history of significant medical disease, such as diabetes mellitus, chronic liver disease, atherosclerosis, hypertension, thromboembolism, or infectious disease, nor had any subject received medication that could affect the evaluation. All were nonsmokers. Women with the following conditions were excluded from the trial: bleeding of undiagnosed cause, oncotic colpocytology, findings suggesting malignant disease of the breast, known or suspected estrogen-dependent tumors or fibroids, alcoholism, Rotor or Dubin-Johnson syndrome, severe liver or kidney disorders, and endometrial hyperplasia. Written informed consent was obtained from all subjects. This protocol was approved by the Ethical Medicine Committee at our hospital. Medication Patients were assigned to one of three treatment groups. Group I, consisting of 20 women who had undergone a hysterectomy, received 0.625 mg/day conjugated equine estrogen (CEE) (Premarin, Wyeth-Ayerst Canada, Montreal, Quebec, Canada). The remaining 40 women were randomly assigned to one of the other two treatment regimens. Group II (n = 20) received sequential combined 0.625 mg/day CEE for 21 days plus 200 mg/day micronized progesterone (MP; Utrogestan, Laboratories Besins-Iscovesco, Paris, France) for the final 10 days (days 11 to 21) and then no medication for 7 days. Group III (n = 20) received sequential combined 0.625 mg/day CEE for 21 days plus 10 mg/day medroxyprogesterone acetate (MPA; Provera, Pharmacia & Upjohn Company, Kalamazoo, MI, USA) for the final 10 days (days 11 to 21) and then no medication for 7 days. All patients completed a 12-cycle HRT course. Laboratory tests Fasting blood samples were collected before treatment and at 24 and 48 weeks. Blood samples were drawn from an antecubital vein using a 20-gauge needle and were placed in anticoagulant solution (9 ml of whole blood to 1 ml of 3.8% sodium citrate solution). Citrated plasma was prepared for measurement of coagulation and fibrinolytic markers by centrifugation at 4 C for 20 minutes at 1,600g, and samples were stored at 80 C before use. Serum was isolated and stored at 4 C for evaluation of the lipoprotein profile. Total cholesterol and triglyceride concentrations were determined using an enzymatic method with an automatic analyzer (Beckman Synchron CX 7, Beckman Coulter Inc, Fullerton, CA, USA). High-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C) levels were determined by an electrophoretical method, using the HDL Cholesterol Supply Kit (Helena Laboratory, Beaumont, TX, USA). Plasma concentrations of tissue plasminogen activator (TPA) and plasminogen activator inhibitor-1 (PAI-1) were determined by enzyme immunoassay (BIA-t-PA, Chromogenix, Mölndal, Sweden; and Thrombonostika PAI-1, Organon Teknika, Boxtel, 81
L.F. Teng, et al Holland, respectively). The plasma levels of fibrinogen, factor VII, and protein S were established using a clotting assay (Fibrinogen Assay, Dade Diagnostico, Aguada, Puerto Rico, USA; Factor VII DP, Behringwerke, Marburg, Germany; and StaClot Protein S, Diagnostica Stago, Asnieres-Sur-Seine, France; respectively). Concentrations of antithrombin III and protein C were determined using a chromogenic assay (Berichrom Antithrombin III, Dade Behring SA, Paris la Defense, France; and Berichrom Protein C, Dade Behring AG, Düdingen, Switzerland, respectively). Statistical methods Data are expressed as mean ± standard deviation. Data were analyzed using the Wilcoxon signed-rank test to compare each variable before and after medication within each group. Treatment group comparisons for differences from baseline results were made using the Kruskal-Wallis test and further by post hoc multiple comparisons (Wilcoxon 2-sample test). Statistical significance was accepted at p less than 0.05. Results Study population Patient characteristics, including age, body mass index, and duration of menopause, were similar in all groups (Table 1). In addition, lipoprotein profiles and hemostatic factors before HRT did not differ significantly among the three groups. Lipid profile Changes in the lipid profiles in the three groups are shown in Table 2. After 12 months of treatment, there were no significant changes in total cholesterol or HDL- C within the three groups. The LDL-C levels (p < 0.0001 and p = 0.042 at 6 and 12 months, respectively) and the atherogenic ratios of total cholesterol/hdl-c (p = 0.02 at 6 months) and LDL-C/HDL-C (p < 0.001 and p = 0.004 at 6 and 12 months, respectively) were significantly reduced with CEE (group I), whereas there were no statistically significant changes with combined HRT (groups II and III). There was a significant difference in LDL-C, total cholesterol/hdl-c, and LDL-C/HDL-C between groups I and II (p = 0.02) as well as between groups I and III (p = 0.01), but no differences were noted between groups II and III. Triglyceride levels increased significantly in group I (p = 0.01 and p = 0.007 at 6 and 12 months, respectively), whereas with combined HRT (groups II and III), there were no statistically significant changes. After 12 months of treatment, the difference in triglycerides was statistically significant between groups I and II (p = 0.01), but not between groups I and III (p = 0.31) or between groups II and III (p = 0.12). Hemostatic factors Hemostatic data are shown in Table 3. After 12 months of CEE treatment (group I), TPA concentrations were reduced (p = 0.007 and p < 0.001 at 6 and 12 months, respectively), whereas the TPA levels did not change in patients treated with combined HRT (groups II and III). Although there was no statistically significant decrease in PAI-1, the reduction in PAI-1 was more pronounced in group I than in groups II and III. There were no significant differences in TPA and PAI-1 among the three groups. After 12 months, there were no statistically significant changes in fibrinogen or factor VII in any of the three groups. Differences in factor VII were statistically significant between groups I and II (p = 0.004), as well as between groups I and III (p = 0.04). In group I, antithrombin III (p = 0.007) and protein S (p = 0.002) were reduced after 6 months but were not changed after 12 months. After 12 months of combined HRT, antithrombin III increased (group II: p = 0.002; group III: p = 0.03). There was a significant difference in antithrombin III between groups I and II (p = 0.01). At 6 months, protein S had increased in group III (p = 0.021). There was a statistical difference in protein S between groups I and II (p = 0.004), as well as between groups I and III (p < 0.001). The increase in protein C was more pronounced in patients in group I (p < 0.001) than in those treated with combined HRT (groups II and III). There was a statistically significant difference in protein C between Table 1. Patient characteristics for three hormone replacement therapy groups Group Age (yr) Period of menopause (yr) Body mass index (kg/m 2 ) I 50.5 ± 3.2 (45 55) 4.9 ± 3.5 (2 14) 25.8 ± 3.9 II 53.1 ± 3.3 (46 57) 4.2 ± 2.4 (2 10) 23.0 ± 2.7 III 50.1 ± 3.6 (45 55) 3.9 ± 2.6 (2 9)q 23.8 ± 4.0 Values are mean ± standard deviation (range). I = conjugated equine estrogen (CEE) alone; II = CEE plus micronized progesterone; III = CEE plus medroxyprogesterone acetate. 82
HRT & Cardiovascular Risk Factors Table 2. Effects of three hormone replacement therapy regimens on lipoprotein profile I II III Mean ± SD % change Mean ± SD % change Mean ± SD % change Total cholesterol (mg/dl) Baseline 223.6 ± 28.0 212.1 ± 28.5 219.4 ± 31.6 6 months 214.5 ± 34.6 4.1 202.3 ± 28.0 4.6 217.4 ± 28.8 0.9 0.531 12 months 212.7 ± 25.4 4.9 206.7 ± 23.9 2.5 207.3 ± 26.1 5.5 0.757 Triglycerides (mg/dl) Baseline 184.4 ± 29.0 176.0 ± 24.3 176.1 ± 26.3 6 months 110.6 ± 46.7 31.1 a 168.1 ± 28.3 10.4 176.1 ± 34.3 0.1 0.131 12 months 117.3 ± 70.1 39.0 b 164.6 ± 26.0 14.9 186.6 ± 47.3 13.8 0.039 HDL-C (mg/dl) Baseline 153.1 ± 13.4 163.8 ± 16.1 160.9 ± 14.7 6 months 157.4 ± 14.1 8.1 163.1 ± 15.3 1.1 156.9 ± 13.4 6.5 0.18 12 months 156.1 ± 12.9 5.7 163.3 ± 19.0 0.8 163.4 ± 14.4 14.2 0.66 LDL-C (mg/dl) Baseline 152.1 ± 26.8 133.6 ± 29.5 143.7 ± 38.1 6 months 132.0 ± 31.4 13.2 c 126.1 ± 27.9 5.6 143.3 ± 28.8 0.3 0.041 12 months 135.7 ± 24.7 10.8 d 141.9 ± 26.5 6.2 142.6 ± 34.1 0.8 0.042 Cholesterol/HDL-C Baseline 14.5 ± 1.3 13.5 ± 0.8 13.8 ± 1.1 6 months 14.0 ± 1.1 9.9 e 13.4 ± 0.8 3.8 14.0 ± 1.1 16.4 0.019 12 months 14.0 ± 1.0 11.1 13.7 ± 1.0 4.9 13.7 ± 1.1 0.8 0.068 LDL-C/HDL-C Baseline 13.1 ± 1.0 12.2 ± 0.6 12.5 ± 1.0 6 months 12.5 ± 0.9 18.4 c 12.1 ± 0.8 3.9 12.7 ± 1.0 16.7 0.001 12 months 12.5 ± 0.8 18.8 f 12.4 ± 0.8 9.7 12.4 ± 0.9 4.2 0.011 *Kruskal-Wallis test on change from baseline among groups. Wilcoxon signed-rank test compares results before and after medication within each group: a p = 0.01; b p = 0.007; c p < 0.001; d p = 0.042; e p = 0.02; f p = 0.004. I = conjugated equine estrogen (CEE) alone; II = CEE plus micronized progesterone; III = CEE plus medroxyprogesterone acetate; SD = standard deviation; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol. p* groups I and II (p = 0.002 and p < 0.001 at 6 and 12 months, respectively), as well as between groups I and III (p = 0.02 and p = 0.002 at 6 and 12 months, respectively). There was no statistical difference in protein C between groups II and III (p = 0.22 and p = 0.12 at 6 and 12 months, respectively). Discussion Our results provide experimental evidence which confirms the findings of many other studies, that estrogen replacement therapy (ERT) has beneficial effects on the lipid profile and fibrinolytic factors in postmenopausal women, and that these effects are diminished by the addition of progestins. There was no significant difference in these effects when using MP or MPA. However, the 1-year effects of ERT or HRT on the overall factors related to venous thromboembolism remained positive. This study was performed in a comparative and partially randomized (only groups II and III) fashion, and all blood samples were analyzed by the same laboratory according to the latest guidelines. The sample size fulfilled the minimum requirements for statistical analysis. This study provides the most unequivocal evidence to date that unopposed estrogen has a more favorable effect on lipoprotein metabolism than estrogen combined with natural or synthetic progestogens. In postmenopausal women receiving HRT, mean LDL-C levels and atherogenic indices (total cholesterol/hdl-c and LDL-C/HDL-C) were significantly lowered, more so in patients treated with CEE alone than in those receiving CEE plus MPA or MP. In addition, the study showed that treatment with CEE alone had a more favorable effect on HDL-C than treatment with CEE combined with progestogens, although the differences did not reach statistical significance. These results are in concordance with the Postmenopausal Estrogen/ 83
L.F. Teng, et al Progestin Interventions (PEPI) study [6], in which the beneficial effects on lipoprotein profiles, except triglycerides, induced by unopposed estrogen were mildly blunted by the addition of progestogens, including MPA and MP. Although some reports have suggested that natural progesterone has no significant effect on plasma levels of lipoprotein [9,10], no significant difference in lipoprotein metabolism was noted between patients receiving MPA and MP in the present study as well as in the PEPI trial [6]. Our results are compatible with those of other studies [2,9,11,12], in which the use of CEE alone increased the plasma triglyceride level in postmenopausal women. An increase in serum triglyceride concentration might have been expected due to the ability of oral estrogen to induce a modest increase in hepatic VLDL secretion, particularly of large VLDL. Large VLDL is directly catabolized by the liver rather than delipidated to small VLDL and LDL, and therefore increased concentrations might not be atherogenic. This also confirms the findings of several previous studies [2,12 14], but not all [6,15], which found that MPA or MP blunts this effect. In this study, although triglyceride levels increased non-significantly in the MPA group after 12 months of treatment, there was no statistical difference in triglyceride levels between the MPA and MP groups. Since lipoprotein lipase is primarily responsible for the degradation of triglyceride-rich lipoprotein, the most visible consequences of high lipoprotein lipase activity are low total triglyceride and high HDL-C plasma levels. Table 3. Effects of three hormone replacement therapy regimens on hemostatic factors I II III Mean ± SD % change Mean ± SD % change Mean ± SD % change TPA (ng/ml) Baseline 13.8 ± 1.5 13.4 ± 1.3 13.5 ± 0.9 6 months 12.7 ± 0.7 30.2 a 13.0 ± 1.5 11.5 13.9 ± 0.9 15.0 0.558 12 months 12.7 ± 0.6 29.4 b 12.8 ± 1.3 17.9 13.4 ± 1.2 6.4 0.671 PAI-1 (ng/ml) Baseline 17.6 ± 6.7 19.8 ± 6.1 19.8 ± 6.7 6 months 10.2 ± 5.6 42.1 18.2 ± 4.2 15.9 18.7 ± 5.6 11.6 0.377 12 months 10.3 ± 4.2 41.5 16.4 ± 4.4 34.3 18.7 ± 6.9 11.1 0.434 Fibrinogen (ng/ml) Baseline 266.4 ± 51.3 279.6 ± 49.5 257.9 ± 40.4 6 months 254.1 ± 32.0 4.6 286.7 ± 47.2 2.5 270.4 ± 40.1 4.9 0.398 12 months 278.4 ± 45.1 4.5 282.9 ± 44.1 1.2 264.4 ± 36.0 2.5 0.600 Factor VII (%) Baseline 114.1 ± 13.8 122.5 ± 18.5 108.9 ± 21.4 6 months 120.3 ± 27.3 5.4 116.3 ± 19.3 5.1 110.3 ± 16.0 1.2 0.225 12 months 1123.5 ± 121.2 8.2 111.4 ± 19.6 9.1 100.7 ± 22.0 7.6 0.014 Antithrombin III (%) Baseline 97.6 ± 8.7 99.0 ± 7.5 195.9 ± 9.91 6 months 92.4 ± 8.2 5.3 c 101.2 ± 11.1 2.2 97.0 ± 7.4 1.2 0.039 12 months 198.6 ± 13.2 1.1 106.7 ± 10.9 7.8 d 102.7 ± 5.51 7.1 e 0.057 Protein C (%) Baseline 193.5 ± 17.1 109.2 ± 20.1 100.4 ± 15.1 6 months 127.1 ± 20.5 36.0 b 114.2 ± 24.8 4.6 110.4 ± 18.5 10.0 0.004 12 months 135.0 ± 24.7 44.4 b 113.1 ± 20.9 3.6 120.1 ± 18.0 19.7 f 0.000 Protein S (%) Baseline 192.9 ± 17.3 183.9 ± 14.6 80.7 ± 5.3 6 months 180.1 ± 17.9 13.8 g 192.5 ± 13.5 10.2 192.3 ± 12.2 14.3 h 0.001 12 months 194.5 ± 16.1 1.7 195.1 ± 16.2 13.3 190.9 ± 16.8 12.7 0.201 *Kruskal-Wallis test on change from baseline among groups. Wilcoxon signed-rank test compares results before and after medication within each group: a p = 0.007; b p < 0.001; c p = 0.007; d p = 0.002; e p = 0.03; f p = 0.011; g p = 0.002; h p = 0.021. I = conjugated equine estrogen (CEE) alone; II = CEE plus micronized progesterone; III = CEE plus medroxyprogesterone acetate; SD = standard deviation; TPA = tissue plasminogen activator; PAI-1 = plasminogen activator inhibitor-1. p* 84
HRT & Cardiovascular Risk Factors Based on our findings, it is possible that MPA may have less of an effect on the activity of lipoprotein lipase than MP, although this requires further evaluation. Recent evidence reveals that impaired fibrinolytic function, as evidenced by increased plasma concentrations of PAI-1 and TPA antigen, is associated with coronary artery disease [16,17]. The explanation for the association between a high level of TPA antigen and a higher incidence of cardiovascular disease is possibly related to the TPA antigen assay, which may detect circulating complexes of inactive TPA and PAI-1 [18]. Observational studies have suggested an association between HRT and increased fibrinolytic potential [19 22], but experimental data are scarce. Our study showed that unopposed oral CEE significantly decreased TPA and PAI-1 levels. Prior studies in postmenopausal women receiving estrogen demonstrated improvement in fibrinolytic potential consistent with our findings [21,23]. However, as reported by Gebara et al [21], there were no significant changes in TPA and PAI-1 concentrations between CEE treatment alone and combined treatment with CEE and progestin. In the present study, the addition of progestogens slightly blunted the effects of CEE alone. There were no differences in fibrinolytic factors between the group receiving MPA and that receiving MP. Some coagulation factors, such as fibrinogen and factor VII, may play an important role in the pathogenesis of coronary artery disease [24]. Our study failed to detect a statistically significant difference in changes in fibrinogen levels among patients receiving CEE alone (group I) and those using combined CEE with either MP or MPA (groups II and III). This is compatible with the PEPI trial [6] and other studies [25,26], in which there was no significant difference in plasma fibrinogen concentrations between active treatments. There are conflicting results regarding factor VII. It has been reported that factor VII increases with unopposed oral CEE [25], but no significant changes occurred with combined HRT [26,27]. However, our study, as well as another randomized trial [28], demonstrated that higher factor VII activity was attributable to CEE alone as compared with CEE combined with progestogen, although there was no significant change in factor VII during HRT in the present study. It has been suggested that triglyceride activates phospholipase C-sensitive factor VII complexes [29]. This suggestion is also supported by the report that the increase in triglyceride levels during the use of oral CEE alone is responsible for the parallel change in factor VII [2,28]. In a review of the literature on venous thrombosis, we noted that conflicting results have been reported. Prior to 1996, epidemiologic studies did not demonstrate a positive association between ERT and venous thrombosis [29,30]. In contrast, four recent observational studies reported that HRT increases the risk of idiopathic venous thromboembolism [8,31 34]. These studies also demonstrated that the risk of venous thromboembolism seemed to be restricted to the first year of use, both in those with and without major risk factors for venous thromboembolism [8,32 35]. However, there is still a lack of complete experimental evaluation of this condition. Deficiencies in antithrombin III, protein C, and protein S can all predispose individuals to venous thromboembolism. In our study, antithrombin III and protein S were significantly reduced with CEE alone in the first 6 months of treatment, as previously reported [35,36], but returned to baseline levels after 12 months of HRT. In contrast, significant increases in antithrombin III and protein S were noted with combined HRT, which was compatible with our previous study of postmenopausal women receiving estradiol valerate plus MPA [37]. In the present study, the increase in protein C was more pronounced in patients using CEE alone than in those using combined HRT. However, significant correlations were observed among protein S, protein C, antithrombin III, factor VII, and fibrinogen, which are factors related to thromboembolism. The net effect after 1 year of ERT or combined HRT in this study was compatible with the concept that HRT causes no appreciable increase in venous thromboembolism over the long term. These experimental results conflict with the observational studies of HERS [8] and the Women s Health Initiative (WHI) [38], in which elderly women receiving CEE plus MPA had an increased incidence of venous thromboembolism after about a 5-year followup. Since there was a lack of experimental data to show the changes in coagulational and anticoagulational factors in patients in HERS and WHI, whether the differences between our study and HERS or WHI are related to the conditions of patients, such as women with existing cardiovascular disease or age, or duration of follow-up, requires further evaluation. However, from the present experimental data, the possibility of an increased risk of venous thromboembolism in the first year of ERT should still be considered. In conclusion, this study confirms that ERT may have a cardioprotective effect in postmenopausal women, based on positive effects on lipoprotein and fibrinolytic activity. The addition of both natural and synthetic progestogens attenuated the effects of estrogen on lipoprotein and fibrinolytic factors, but still resulted in beneficial effects on triglycerides. The 1-year effects of hormone therapy on overall factors related to venous thromboembolism were positive. Furthermore, MP was not superior to MPA. 85
L.F. Teng, et al References 1. Speroff L. Quality of life issues in the management of the menopause. In: Popkin D, Peddle L, eds. Women s Health Today. New York: Parthenon, 1994:271 290. 2. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069 1075. 3. Grodstein F, Stampfer MJ. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199 210. 4. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453 461. 5. Buch TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell D Jr, ed. Menopause: Physiology and Pharmacology. Chicago: Medical Year Book, 1986:187 208. 6. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273: 199 208. 7. Sarrel PM. Blood flow. In: Lobo RA, ed. Treatment of Postmenopausal Women: Basic and Clinical Aspects. New York: Raven Press, 1994:251 262. 8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605 613. 9. Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogen and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987;156:66 71. 10. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151: 746 750. 11. Gambrell RD Jr, Teran AZ. Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 1991;165:307 317. 12. Barrett-Connor E, Wingard D, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA 1989;261:2095 2100. 13. Farish E, Fletcher CD, Hart DM, Teo HT, Alazzawi F, Howie C. The effects of conjugated equine oestrogens with and without a cyclical progestogen on lipoproteins, and HDL subfractions in postmenopausal women. Acta Endocrinol 1986; 113:123 127. 14. Jensen J, Nilas L, Christiansen C. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. Br J Obstet Gynecol 1986;93:613 618. 15. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the postmenopausal patient. Obstet Gynecol 1987; 69:929 932. 16. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241 2247. 17. Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand J Clin Lab Invest 1999;59(Suppl 230):23 31. 18. Juhan-Vague I, Rijken DC, de Cook F, Mendez C, Collen D. Extrinsic plasminogen activators in clinical plasma samples. Prog Fibrinol 1983;6:65 69. 19. Grimaus M, Roisin JP, Vissac AM, Amiral J. Performance characteristics of a global assay for evaluating blood fibrinolytic potential. Fibrinolysis 1996;10:S3. (Abstract 95) 20. Meilahn EN, Cauley JA, Tracy PR, Macy EO, Gutai JP, Kuller LH. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 1996;143:159 166. 21. Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952 1958. 22. Shahar E, Folsom AR, Salomaa VV, et al. Relation of hormone replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996;93:1970 1975. 23. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992;2:445 455. 24. Scarabin PY. Haemostatic variables and arterial thrombotic disease: epidemiological evidence. In: Seghatchian MJ, Samama MM, Hecker SP, eds. Hypercoagulable States: Fundamental Aspects, Acquired Disorders, and Congenital Thrombophilia. Boca Raton: CRC Press, 1996:209 216. 25. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994;71:420 423. 26. Conard J, Basedevant A, Thomas JL, Ochsenbein E, Denis C, Guyene TT, Degrelle H. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebocontrolled study with nomegestrol acetate and estradiol. Fertil Steril 1995;64:957 962. 27. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/ progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized control trial. Arterioscler Thromb Vasc Biol 1997;17:3071 3078. 28. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council s General Practice Research Framework. BMJ 1996;312:473 478. 29. Skartlien AH, Lyberg-Beckmann S, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels on factor VIIphospholipid complexes in plasma. Arteriosclerosis 1989;9: 798 801. 30. Devor M, Barret-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992;92:275 282. 31. Lowe GD, Greer IA, Cooke TG. Risk and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ 1992;305:567 574. 86
HRT & Cardiovascular Risk Factors 32. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977 980. 33. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348:981 983. 34. Gutthann SP, Garcia Rodriguez LA, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population-based case-control study. BMJ 1997;314:796 800. 35. Boschetti C, Cortellaro M, Nencioni T, Bertolli V, Della-Volpe A, Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs. oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res 1991;62:1 8. 36. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 1997;77:770 780. 37. Chen FP, Lee N, Wang CH, Cherng WJ, Soong YK. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998;69:267 273. 38. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA 2002;288: 321 333. 87